YEEHAW CANDIDATES Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: J.F. who wrote (21828)	1/11/2007 6:07:11 PM
From: J.F.	Read Replies (1) of 23958

Memory Pharmaceuticals Corp. (MEMY) expects to start a Phase I clinical trial for MEM 63908 in the second half of 2007, the biopharmaceutical company said Thursday in a Securities and Exchange Commission filing. MEM 63908 is the Montvale, N.J., company's second named drug candidate in the Nicotinic Alpha-7 Agonist program, the filing said. MEM 63908 could be beneficial in the treatment of Alzheimers's disease, the company's Web site said. Memory Pharmaceuticals is developing drugs to treat other central nervous system disorders, many of which hurt memory and other cognitive function. The company's shares closed Thursday at $3.70 each, up 11 cents.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next